An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty

Trial Profile

An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs IONIS FXIRx (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2014 Results published in the New England Journal of Medicine.
    • 29 Aug 2014 Status changed from active, no longer recruiting to completed.
    • 04 Aug 2014 According to an Isis Pharmaceuticals media release, full data analysis will be reported in an upcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top